Stay updated with breaking news from Zemer Gitai. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Compound called lolamicin targets a group of harmful microbes but does not disturb those that live peacefully in the gut. Compound called lolamicin targets a group of harmful microbes but does not disturb those that live peacefully in the gut.
/PRNewswire/ -- As the investment division of Viva Biotech, Viva BioInnovator is committed to being a collaborative platform for Innovative Biotech companies...
Funding will advance discovery of novel antibiotics addressing antimicrobial resistance.
PRINCETON, N.J.--(BUSINESS WIRE)--Mar 24, 2022--
Anti-infective drug discovery startup ArrePath has launched with $20 million in seed funding to advance the development of molecules that use a dual mechanism to kill bacteria. The Princeton University spinout says its approach could overcome the drug resistance bacteria are developing to currently available products.